Clinical review report: Apomorphine hydrochloride (Kynmobi) (Sunovion Pharmaceuticals Canada Inc.) indication: the acute, intermittent treatment of "OFF" episodes in patients with Parkinson disease
The objective of the current CADTH Common Drug Review was to perform a systematic review of the beneficial and harmful effects of apomorphine hydrochloride sublingual film (Kynmobi) for the acute, intermittent treatment of OFF episodes in patients with Parkinson disease
| Corporate Author: | |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
2021, April 2021
|
| Edition: | Final (with redactions) |
| Series: | CADTH common drug review
|
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | The objective of the current CADTH Common Drug Review was to perform a systematic review of the beneficial and harmful effects of apomorphine hydrochloride sublingual film (Kynmobi) for the acute, intermittent treatment of OFF episodes in patients with Parkinson disease |
|---|---|
| Physical Description: | 1 PDF file (99 pages) illustrations |